Aligos Therapeutics (ALGS) Equity Ratio (2019 - 2026)

Aligos Therapeutics has reported Equity Ratio for 8 years, with the latest figure at 0.49 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 36.27% year-over-year to 0.49; the trailing twelve-month figure through Mar 2026 stood at 0.49 (down 36.27% YoY), and the FY2025 full-year result was 0.6, up 246.32% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.49, down from 0.6 in the prior quarter.
• The five-year high for Equity Ratio was 0.77 in Q1 2025, with the low at 0.41 in Q4 2024.
• Historically, Equity Ratio has averaged 0.59 across 5 years, with a median of 0.65 in 2025.
• Annual changes were most pronounced in 2024 — Equity Ratio tumbled 168.02% — and 2025, when it surged 246.32%.
• Aligos Therapeutics' Equity Ratio stood at 0.71 in 2022, then retreated by 14.2% to 0.61 in 2023, then plunged by 168.02% to 0.41 in 2024, then surged by 246.32% to 0.6 in 2025, then decreased by 18.58% to 0.49 in 2026.
• The last three Equity Ratio figures came in at 0.49 (Q1 2026), 0.6 (Q4 2025), and 0.65 (Q3 2025), per Business Quant data.